Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd has demonstrated a positive financial outlook, highlighted by a 4% sequential revenue increase to $174.4 million in 4Q25, along with an 8% year-over-year growth to a total of $655.4 million for the full year 2025. Notably, the growth in prescriptions for Optune Lua in non-small cell lung cancer (NSCLC) by 8% signifies increasing adoption of its products, while the receipt of national reimbursement in Spain is anticipated to further enhance revenue streams in 2026. Additionally, the company expects ongoing US growth driven by improved sales dynamics and contributions from clinical trials, positioning itself favorably within the oncology treatment market.

Bears say

NovoCure Ltd is experiencing a downward revision in revenue estimates, with the projected revenue for glioblastoma reduced to $690 million from $702 million and total revenue adjusted down to $711.3 million from $738.9 million for 2026. Key risks contributing to this negative outlook include poor sales adoption of Optune devices, potential clinical failures of Tumor Treating Fields technologies across various indications, and increased competition from other treatment options. Additionally, there are concerns regarding the efficacy of clinical programs, potential safety signals, and regulatory challenges that may impact the company's future financial performance.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.